EPS (Diluted) for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current diluted EPS (TTM) is $41.56. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEPS (Diluted)Switch metric
TTM (last 4 quarters)
$41.56
YoY change
+8.2%
5Y CAGR
+6.3%
Peak year (2021)
$71.97
Latest annual
$41.48
EPS (Diluted) history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
EPS (Diluted) history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | EPS (Diluted) | YoY |
|---|---|---|---|---|
| 2025 | $41.48 | +8.2% | ||
| 2024 | $38.34 | +10.3% | ||
| 2023 | $34.77 | -9.0% | ||
| 2022 | $38.22 | -46.9% | ||
| 2021 | $71.97 | +135.8% | ||
| 2020 | $30.52 | +65.3% | ||
| 2019 | $18.46 | -13.3% | ||
| 2018 | $21.29 | +105.9% | ||
| 2017 | $10.34 | +34.3% | ||
| 2016 | $7.70 | +39.5% | ||
| 2015 | $5.52 | +85.2% | ||
| 2014 | $2.98 | -19.9% | ||
| 2013 | $3.72 | -44.9% | ||
| 2012 | $6.75 | -375.5% | ||
| 2011 | $-2.45 | +94.4% | ||
| 2010 | $-1.26 | +48.2% | ||
| 2009 | $-0.85 | -19.0% | ||
| 2008 | $-1.05 | -34.0% | ||
| 2007 | $-1.59 | -10.2% | ||
| 2006 | $-1.77 | +3.5% | ||
| 2005 | $-1.71 | -331.1% | ||
| 2004 | $0.74 | -134.7% | ||
| 2003 | $-2.13 | -24.7% | ||
| 2002 | $-2.83 | +56.4% | ||
| 2001 | $-1.81 | +174.2% | ||
| 2000 | $-0.66 | -9.6% | ||
| 1999 | $-0.73 | +160.7% | ||
| 1998 | $-0.28 | -30.0% | ||
| 1997 | $-0.40 | -69.7% | ||
| 1996 | $-1.32 | +10.9% | ||
| 1995 | $-1.19 | -26.5% | ||
| 1994 | $-1.62 | -32.8% | ||
| 1993 | $-2.41 | +94.4% | ||
| 1992 | $-1.24 | +327.6% | ||
| 1991 | $-0.29 | +38.1% | ||
| 1990 | $-0.21 | — |
EPS (Diluted) values are taken from Regeneron Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported diluted EPS of $41.48 – grew 8.2% year-over-year.
Through 2020–2025 (5 years), Regeneron Pharmaceuticals diluted EPS delivered a +6.3% annualised rate; sustaining 2 straight years of year-over-year growth.
Between 2021 and 2025, Regeneron Pharmaceuticals diluted EPS plunged 42.4%, falling from $71.97 to $41.48.
$71.97 stands as the all-time-high annual diluted EPS, posted in 2021, against a low of $-2.83 during 2002.
Among 8 Healthcare peers, Regeneron Pharmaceuticals (REGN) ranks 1st; the peer median for diluted EPS is $13.16.
Regeneron Pharmaceuticals EPS (Diluted) by Year
Regeneron Pharmaceuticals EPS (Diluted) 2025: $41.48
Regeneron Pharmaceuticals diluted EPS in 2025 was $41.48, grew 8.2% from 2024.
Regeneron Pharmaceuticals EPS (Diluted) 2024: $38.34
Regeneron Pharmaceuticals diluted EPS in 2024 was $38.34, grew 10.3% from 2023.
Regeneron Pharmaceuticals EPS (Diluted) 2023: $34.77
Regeneron Pharmaceuticals diluted EPS in 2023 was $34.77, declined 9.0% below 2022.
Regeneron Pharmaceuticals EPS (Diluted) 2022: $38.22
Regeneron Pharmaceuticals diluted EPS in 2022 was $38.22, plunged 46.9% below 2021.
Regeneron Pharmaceuticals EPS (Diluted) 2021: $71.97
Regeneron Pharmaceuticals diluted EPS in 2021 was $71.97.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — EPS (Diluted)
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest diluted EPS.
| Company | EPS (Diluted) | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $23.03 | Healthcare |
| Eli Lilly and Company (LLY) | $22.95 | Healthcare |
| Amgen Inc. (AMGN) | $14.23 | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $13.23 | Healthcare |
| AstraZeneca PLC (AZN) | $13.08 | Healthcare |
| Johnson & Johnson (JNJ) | $11.03 | Healthcare |
| Merck & Co., Inc. (MRK) | $7.28 | Healthcare |
| AbbVie Inc. (ABBV) | $2.37 | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's diluted EPS?
- Latest reported diluted EPS for Regeneron Pharmaceuticals (REGN) is $41.56 (period ending December 31, 2025).
How has Regeneron Pharmaceuticals diluted EPS changed year-over-year?
- Regeneron Pharmaceuticals (REGN) diluted EPS changed +8.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals diluted EPS?
- Regeneron Pharmaceuticals (REGN) diluted EPS compound annual growth rate is +6.3% over the most recent 5 years available.
When did Regeneron Pharmaceuticals diluted EPS hit its highest annual value?
- Regeneron Pharmaceuticals diluted EPS reached its highest annual value of $71.97 in 2021.
What was Regeneron Pharmaceuticals diluted EPS in 2024?
- Regeneron Pharmaceuticals (REGN) diluted EPS in 2024 was $38.34.
What was Regeneron Pharmaceuticals diluted EPS in 2025?
- Regeneron Pharmaceuticals (REGN) diluted EPS in 2025 was $41.48.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.